Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

Publisher: John Wiley & Sons Inc

E-ISSN: 1097-0142|120|7|968-975

ISSN: 0008-543x

Source: CANCER, Vol.120, Iss.7, 2014-04, pp. : 968-975

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract